New Three-Drug cocktail shows promise for Hard-to-Treat lung cancer
NCT ID NCT04340882
First seen Nov 05, 2025 · Last updated May 01, 2026 · Updated 18 times
Summary
This study is for people with advanced non-small cell lung cancer whose disease got worse after standard chemotherapy and immunotherapy. It tests a combination of three drugs: docetaxel (chemotherapy), ramucirumab (blocks blood vessel growth to tumors), and pembrolizumab (helps the immune system attack cancer). The goal is to see if this triple therapy is safe and works better than current options. About 30 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Grady Health System
Atlanta, Georgia, 30303, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.